Announcing the New Cancer Therapy Advisor Print Edition
We want to provide you with another useful, enduring resource that delivers relevant, up-to-date oncology information.
We want to provide you with another useful, enduring resource that delivers relevant, up-to-date oncology information.
Twitter is a great way for oncology professionals to interact with their peers and patients, and CTA has recommendations for some feeds you should be following.
Chemotherapy Advisor is changing its name to better reflect the changing landscape of cancer care.
Ibrutinib has been given breakthrough therapy designation for treatment of mantle cell lymphoma.
Although studies are still in their infancy, doctors are using T-cell immunotherapy to attack recurrent leukemic cancer cells, with astonishing results.
Combined anti-HER2 therapy, with or without chemotherapy, does not increase the risk for cardiac toxicities compared to anti-HER2 monotherapy, found research presented at ASCO 2013.
PF-05280014, a potential biosimilar, was found to have an identical amino acid sequence and similar in vitro functional properties as the monoclonal antibody (mAb) trastuzumab, found research presented at ASCO 2013.
Lymphoseek has now demonstrated significant efficacy in diagnosis and staging of squamous cell carcinoma of the head and neck.
A new database of patient information promises to change the way oncologists treat their patients in the future.